Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13213429 | 1.00 | DPP4 (0.38) | DPP4DPP8DPP9KMT2AALOX15 | |
| SCHEMBL26749150 | 0.86 | DPP4 (0.39) | DPP4DPP8DPP9KMT2AALOX15 | |
| SCHEMBL13233971 | 0.86 | DPP4 (0.39) | DPP4DPP8DPP9KMT2AALOX15 | |
| SCHEMBL23771793 | 0.85 | DPP4 (0.36) | DPP4DPP8DPP9KMT2AALOX15 | |
| SCHEMBL22201756 | 0.85 | DPP4 (0.36) | DPP4DPP8DPP9KMT2AALOX15 | |
| SCHEMBL22844805 | 0.82 | — | — | |
| SCHEMBL22479743 | 0.82 | FOLH1 (0.44) | FOLH1 | |
| SCHEMBL21152873 | 0.82 | FOLH1 (0.44) | FOLH1 | |
| SCHEMBL278867 | 0.82 | — | — | |
| SCHEMBL7602617 | 0.82 | FOLH1 (0.44) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | US | disclosed |
| US-11780900-B2 | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | Janssen Sciences Ireland Unlimited Company (IE) | 2023-10-10 | — | — | US | disclosed |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-26 | — | — | US | disclosed |
| US-11732019-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-22 | — | — | US | disclosed |
| US-11591379-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-28 | — | — | US | disclosed |
| US-20210253661-A1 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2021-08-19 | — | — | US | disclosed |
| US-20210206822-A1 | Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-08 | — | — | US | disclosed |
| US-20210163566-A1 | Antibody-Coupled Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-03 | — | — | US | disclosed |
| US-10968265-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-06 | — | — | US | disclosed |
| US-10968264-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-06 | — | — | US | disclosed |
| US-10961293-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICS NV (BE) | 2021-03-30 | — | — | US | disclosed |
| US-10875902-B2 | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-29 | — | — | US | disclosed |
| US-20200283491-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-10 | — | — | US | disclosed |
| US-10640544-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-05 | — | — | US | disclosed |
| US-20190345214-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-14 | — | — | US | disclosed |
| US-20190330296-A1 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
| US-20190298849-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-03 | — | — | US | disclosed |
| US-20180127476-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-10 | — | — | US | disclosed |
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961293-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | DPP4 65/4885DPP8 148/4885DPP9 74/4885 |
| US-20210206822-A1 | Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors | NPY4R, NPY5R, NPY1R | DPP4 65/4885DPP8 148/4885DPP9 74/4885 |
| US-20210253661-A1 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | GLP1R, GIPR, IAPP | DPP4 24/4885DPP8 35/4885DPP9 29/4885 |
| US-20200283491-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | DPP4 760/4885DPP8 704/4885DPP9 482/4885 |
| US-10875902-B2 | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | GLP1R, GIPR, IAPP | DPP4 24/4885DPP8 35/4885DPP9 29/4885 |
| US-20190298849-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | DPP4 760/4885DPP8 704/4885DPP9 482/4885 |
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | DPP4 65/4885DPP8 148/4885DPP9 74/4885 |
| US-11732019-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | DPP4 65/4885DPP8 148/4885DPP9 74/4885 |
| US-20180127476-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | DPP4 65/4885DPP8 148/4885DPP9 74/4885 |
| US-10640544-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | DPP4 760/4885DPP8 704/4885DPP9 482/4885 |
| US-11780900-B2 | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | GLP1R, GIPR, IAPP | DPP4 24/4885DPP8 35/4885DPP9 29/4885 |
| US-11591379-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | DPP4 760/4885DPP8 704/4885DPP9 482/4885 |
| US-10968265-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | DPP4 760/4885DPP8 704/4885DPP9 482/4885 |
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | DPP4 760/4885DPP8 704/4885DPP9 482/4885 |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | DPP4 760/4885DPP8 704/4885DPP9 482/4885 |
| US-20210163566-A1 | Antibody-Coupled Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors | NPY1R, NPY5R, NPY2R | DPP4 760/4885DPP8 704/4885DPP9 482/4885 |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | DPP4 760/4885DPP8 704/4885DPP9 482/4885 |
| US-10968264-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | DPP4 65/4885DPP8 148/4885DPP9 74/4885 |
| US-20190345214-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | DPP4 65/4885DPP8 148/4885DPP9 74/4885 |
| US-20190330296-A1 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | GLP1R, GIPR, IAPP | DPP4 24/4885DPP8 35/4885DPP9 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.